US Medicare adds another compendium for cancer treatment
This article was originally published in Scrip
The US Medicare programme has added Elsevier Gold Standard's Clinical Pharmacology compendium to the list of references acceptable to support Part B coverage for off-label use of medicines to treat cancer. The Centers for Medicare and Medicaid Services(CMS) previously announced it would also recognise the National Comprehensive Cancer Network Drugs and Biologics Compendium and the Thomson Micromedex DrugDex for use by local contractors that process and approve coverage under Part B. The CMS has now completed its review of compendia requests received earlier this year and is exploring options for updating compendia relevant to the Part D drug benefit and the joint federal/state Medicaid programme for the poor.
You may also be interested in...
COVID-19 Vaccines: ACIP’s Allocation Proposal Prioritizes Long-Term Care Residents, Essential Workers
First group to receive vaccine would comprise health care personnel and residents of long-term care facilities; next in line are non-health care essential workers, who would take priority over adults with high-risk medical conditions and those ages 65 years and older, according to the CDC advisory committee’s proposed allocation framework.
Although US FDA wants sponsors to maintain blinded Phase III follow-up as long as possible after emergency use authorization or licensure, vaccine researcher Larry Corey says it will become ‘untenable’ to keep individuals in placebo arm once they qualify for vaccine access under the allocation framework.
Industry principles for enhancing diversity in clinical trials call for use of digital data collection tools and flexible scheduling of study site visits to reduce barriers to enrollment, as well as greater involvement of under-represented communities in the trial design planning process and recruitment of investigators with diverse ethnic and racial backrounds.